Effect of Histone Deacetylase Inhibitor JNJ-26481585 in Pain

Journal of Molecular Neuroscience

Volumn 55, Issue 3, 2015, Pages 570-578

  Capasso, Kathryn E ^a,c   Manners, Melissa T ^a   Quershi, Rehman A ^b   Tian, Yuzhen ^a   Gao, Ruby ^a   Hu, Huijuan ^a   Barrett, James E ^a   Sacan, Ahmet ^b   Ajit, Seena K ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b DREXEL UNIVERSITY   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Chemotherapy; Histone deacetylase inhibitor; JNJ 26481585; Pain

Indexed keywords

4 AMINOBUTYRIC ACID; AMINE; ANTINEOPLASTIC AGENT; CACNA2D1 PROTEIN, MOUSE; CALCIUM CHANNEL; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; GABAPENTIN; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; QUISINOSTAT;

ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENETICS; HYPERALGESIA; MACROPHAGE; MALE; METABOLISM; MOUSE; NEURALGIA; SPINAL CORD;

AMINES; ANIMALS; ANTINEOPLASTIC AGENTS; CALCIUM CHANNELS; CYCLOHEXANECARBOXYLIC ACIDS; GAMMA-AMINOBUTYRIC ACID; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; HYPERALGESIA; INTERLEUKIN-1BETA; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; NEURALGIA; NF-KAPPA B; SPINAL CORD;

EID: 84939884814     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-014-0391-7     Document Type: Article

References (49)

1. Akimova T, Beier UH, Liu Y, Wang L, Hancock WW (2012) Histone/protein deacetylases and T-cell immune responses. Blood 119:2443–2451
2. Arts J, King P, Marien A, Floren W, Belien A, Janssen L, Pilatte I, Roux B, Decrane L, Gilissen R, Hickson I, Vreys V, Cox E, Bol K, Talloen W, Goris I, Andries L, Du Jardin M, Janicot M, Page M, van Emelen K, Angibaud P (2009) JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res 15:6841–6851
3. Austin PJ, Moalem-Taylor G (2010) The neuro-immune balance in neuropathic pain: Involvement of inflammatory immune cells, immune-like glial cells and cytokines. J Neuroimmunol 229:26–50
4. Bai G, Wei D, Zou S, Ren K, Dubner R (2010) Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia. Mol Pain 6:51
5. Bode KA, Schroder K, Hume DA, Ravasi T, Heeg K, Sweet MJ, Dalpke AH (2007) Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 122:596–606
6. Brogdon JL, Xu Y, Szabo SJ, An S, Buxton F, Cohen D, Huang Q (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 109:1123–1130
7. Cavaletti G, Marmiroli P (2010) Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 6:657–666
8. Chiechio S, Zammataro M, Morales ME, Busceti CL, Drago F, Gereau RWT, Copani A, Nicoletti F (2009) Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain. Mol Pharmacol 75:1014–1020
9. Christo PJ, Mazloomdoost D (2008) Cancer pain and analgesia. Ann N Y Acad Sci 1138:278–298
10. Denk F, Huang W, Sidders B, Bithell A, Crow M, Grist J, Sharma S, Ziemek D, Rice ASC, Buckley NJ, McMahon SB (2013) HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain. Pain 154:1668–1679
11. Denk F, McMahon SB (2012) Chronic pain: emerging evidence for the involvement of epigenetics. Neuron 73:435–444
12. Doehring A, Geisslinger G, Lotsch J (2011) Epigenetics in pain and analgesia: an imminent research field. Eur J Pain 15:11–16
13. Gauchan P, Andoh T, Ikeda K, Fujita M, Sasaki A, Kato A, Kuraishi Y (2009) Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit. Biol Pharm Bull 32:732–734
14. Geranton SM (2012) Targeting epigenetic mechanisms for pain relief. Curr Opin Pharmacol 12:35–41
15. Giger RJ, Hollis ER 2nd, Tuszynski MH (2010) Guidance molecules in axon regeneration. Cold Spring Harb Perspect Biol 2:a001867
16. Grond S, Radbruch L, Meuser T, Sabatowski R, Loick G, Lehmann KA (1999) Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain 79:15–20
17. Haberland M, Montgomery RL, Olson EN (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10:32–42
18. Halili MA, Andrews MR, Labzin LI, Schroder K, Matthias G, Cao C, Lovelace E, Reid RC, Le GT, Hume DA, Irvine KM, Matthias P, Fairlie DP, Sweet MJ (2010) Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol 87:1103–1114
19. Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R, Eilbeck K, Lewis S, Marshall B, Mungall C, Richter J, Rubin GM, Blake JA, Bult C, Dolan M, Drabkin H, Eppig JT, Hill DP, Ni L, Ringwald M, Balakrishnan R, Cherry JM, Christie KR, Costanzo MC, Dwight SS, Engel S, Fisk DG, Hirschman JE, Hong EL, Nash RS, Sethuraman A, Theesfeld CL, Botstein D, Dolinski K, Feierbach B, Berardini T, Mundodi S, Rhee SY, Apweiler R, Barrell D, Camon E, Dimmer E, Lee V, Chisholm R, Gaudet P, Kibbe W, Kishore R, Schwarz EM, Sternberg P, Gwinn M, Hannick L, Wortman J, Berriman M, Wood V, de la Cruz N, Tonellato P, Jaiswal P, Seigfried T, White R (2004) The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res 32:D258–D261
20. Hu H-J, Carrasquillo Y, Karim F, Jung WE, Nerbonne JM, Schwarz TL, Gereau Iv RW (2006) The Kv4.2 potassium channel subunit is required for pain plasticity. Neuron 50:89–100
21. Huang DW, Sherman BT, Lempicki RA (2008) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protocols 4:44–57
22. Hutchinson MR, Shavit Y, Grace PM, Rice KC, Maier SF, Watkins LR (2011) Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev 63:772–810
23. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249–264
24. Jaggi AS, Singh N (2012) Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 291:1–9
25. Kaley TJ, Deangelis LM (2009) Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol 145:3–14
26. Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27–30
27. Kiguchi N, Kobayashi Y, Maeda T, Fukazawa Y, Tohya K, Kimura M, Kishioka S (2012) Epigenetic augmentation of the macrophage inflammatory protein 2/C-X-C chemokine receptor type 2 axis through histone H3 acetylation in injured peripheral nerves elicits neuropathic pain. J Pharmacol Exp Ther 340:577–587
28. Klein R (2009) Bidirectional modulation of synaptic functions by Eph/ephrin signaling. Nat Neurosci 12:15–20
29. Kouzarides T (2007) SnapShot: histone-modifying enzymes. Cell 131:822
30. Levy MH, Chwistek M, Mehta RS (2008) Management of chronic pain in cancer survivors. Cancer J 14:401–409
31. Liang D-Y, Li X, Clark JD (2013) Epigenetic regulation of opioid-induced hyperalgesia, dependence, and tolerance in mice. J Pain 14:36–47
32. Malik B, Stillman M (2008) Chemotherapy-induced peripheral neuropathy. Curr Neurol Neurosci Rep 8:56–65
33. Matsumoto M, Inoue M, Hald A, Xie W, Ueda H (2006) Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin. J Pharmacol Exp Ther 318:735–740
34. Mehlen P, Delloye-Bourgeois C, Chedotal A (2011) Novel roles for slits and netrins: axon guidance cues as anticancer targets? Nat Rev Cancer 11:188–197
35. Pachman DR, Barton DL, Watson JC, Loprinzi CL (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90:377–387
36. Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC (2008) Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 15:3081–3094
37. Pasterkamp RJ, Giger RJ (2009) Semaphorin function in neural plasticity and disease. Curr Opin Neurobiol 19:263–274
38. Polomano RC, Bennett GJ (2001) Chemotherapy-evoked painful peripheral neuropathy. Pain Med 2:8–14
39. Roger T, Lugrin J, Le Roy D, Goy G, Mombelli M, Koessler T, Ding XC, Chanson A-L, Reymond MK, Miconnet I, Schrenzel J, François P, Calandra T (2011) Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 117:1205–1217
40. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101–1108
41. Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ (2011) Histone deacetylases as regulators of inflammation and immunity. Trends Immunol 32:335–343
42. Sweet MJ, Shakespear MR, Kamal NA, Fairlie DP (2012) HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation. Immunol Cell Biol 90:14–22
43. Tong WG, Wei Y, Stevenson W, Kuang SQ, Fang Z, Zhang M, Arts J, Garcia-Manero G (2010) Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor. Leuk Res 34:221–228
44. Tran L, Chaloner A, Sawalha AH, Greenwood Van-Meerveld B (2013) Importance of epigenetic mechanisms in visceral pain induced by chronic water avoidance stress. Psychoneuroendocrinology 38:898–906
45. Venugopal B, Baird R, Kristeleit R, Plummer R, Cowan R, Stewart A, Fourneau N, Hellemans P, Elsayed Y, McClue S, Smit JW, Forslund A, Phelps C, Camm J, Evans TRJ, de Bono JS, Banerji U (2013) A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor, in patients with advanced solid tumors. Clin Cancer Res
46. Ververis K, Karagiannis TC (2011) Potential non-oncological applications of histone deacetylase inhibitors. Am J Trans Res 3:454–467
47. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44:1507–1515
48. Yamamoto Y, Gaynor RB (2001) Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 107:135–142
49. Zhang Z, Cai Y-Q, Zou F, Bie B, Pan ZZ (2011) Epigenetic suppression of GAD65 expression mediates persistent pain. Nat Med 17:1448–1455